

June 26, 2019

Listing Department

Code: **531 335**

BSE LIMITED

P J Towers, Dalal Street, Fort,
Mumbai-400 001

Listing Department

Code: **ZYDUSWELL**

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Sub: Submission of half yearly Disclosure on Related Party Transactions.

Ref: Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements),
Regulations, 2015.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements),
Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis,
in the format specified in the accounting standards for the half year ended March 31, 2019.

This is for your information and records.

Thanking you,

Yours faithfully,

For, **ZYDUS WELLNESS LIMITED**



DHANRAJ P. DAGAR
COMPANY SECRETARY



Transactions during period October 1, 2018 to March 31, 2019 with related parties					
Sr. No.	Nature of Transaction	Value of Transactions [INR- Lakhs]			
		Joint Venture	Key Managerial Personnel	Enterprises significantly influenced by Directors and/ or their relatives	Other entites where significant influence exists
1	Purchase of Goods	-	-	-	-
2	Purchase of Property, Plant and Equipment	-	-	-	-
3	Purchase of Services	-	-	-	-
4	Reimbursement of Expenses paid	-	-	-	134
5	Sale of Goods	-	-	-	19
6	Sale of Property, Plant and Equipment	-	-	-	-
7	Sale of Services	-	-	-	0
8	Reimbursement of Expenses Recovered	-	-	-	-
9	Interest Income	-	-	-	-
10	Interest Expense	-	-	-	4
11	Dividend Received	-	-	-	-
12	Dividend Paid	-	-	-	-
13	Contributions during the year (includes Employee's share and contribution)	-	-	-	-
14	issue of Equity Shares	-	-	-	117,500
15	Borrowings	-	-	-	275
	Outstanding as on March 31, 2019				
16	Outstanding Payable	-	-	-	395
17	Outstanding Receivable	-	-	-	5
18	Remuneration to KMPs and Directors				
(i)	Salaries and other employee benefits to Whole time directors and other executive officers	220.26	-	-	-
(ii)	Commission and Sitting Fees:	118	-	-	-
	Outstanding payable as on 31.03.2019	91	-	-	-
19	Post-Employment Benefits Plan-	Oct 18 to Mar 19			
	Zydus Wellness Limited Employee Group Gratuity Scheme	44	-	-	-
	Heinz India Private Limited Provident Fund [w.e.f January 30, 2019]	73	-	-	-
	Heinz India Private Limited Employee Provident Fund [w.e.f. January 30, 2019]	54	-	-	-



Name of the Related Parties and Nature of the Related Party Relationship:	
a	Holding Company: Cadila Healthcare Limited
b	Subsidiaries Companies:
	Liva Investment Limited
	Liva Nutritions Limited
	Zydus Nutritions Limited [Formerly a Partnership Firm: M/s. Zydus Wellness - Sikkim] * [Refer Note-44 (g)]
	Heinz India Private Limited *[Refer Note-44 (g)]
c	Fellow Subsidiaries/ Concerns:
	Zydus Noveltech Inc., USA
	Hercon Pharmaceutical USA LLC, USA
	Violio Healthcare Limited
	Nesher Pharmaceuticals (USA) LLC, USA
	Acme Pharmaceuticals Private Limited
	Zydus Healthcare SA Pty Limited, South Africa
	Zydus Technologies Limited
	Simayla Pharmaceuticals Pty Limited, South Africa
	Zydus Healthcare Limited
	Script Management Services Pty Limited, South Africa
	Dialforhealth India Limited
	Etna Biotech SRL, Italy
	Dialforhealth Unity Limited
	Zydus France SAS, France
	Dialforhealth Greencross Limited
	Laboratorios Combix S.L., Spain
	Liva Pharmaceuticals Limited
	Zydus Nikkho Pharmaceutica Limitada, Brasil
	Alidac Pharmaceuticals Limited
	Zydus Pharmaceuticals Mexico SA de CV, Mexico
	Zydus Foundation
	Zydus Pharmaceuticals Mexico Services SA de CV, Mexico
	Windlas Healthcare Private Limited
	Zydus Worldwide DMCC, Dubai
	Zydus International Private Limited, Ireland
	Zydus Discovery DMCC, Dubai
	Zydus Netherlands B. V., the Netherlands
	ZAHL Europe B. V., the Netherlands
	Zydus Lanka (Private) Limited, Sri Lanka
	Alidac Pharmaceuticals (Myanmar) Limited, Myanmar
	Zydus Healthcare Philippines Inc., Philippines
	Sentynl Therapeutics Inc., USA
	ZAHL B. V., the Netherlands
	ZyVet Animal Health Inc., USA
	Zydus Pharmaceuticals USA Inc., USA
	Violio Pharmaceuticals Limited
	Zydus Healthcare USA LLC, USA
	Viona Pharmaceuticals Inc., USA
	Windlas, Inc., USA
	US Pharma Windlas LLC, USA
d	Directors:
	Dr. Sharvil P. Patel
	Non -Executive Chairman
	Mr. Ganesh Nayak
	Non-Executive Director
	Prof. Indiraben.J.Parikh
	Independent Director up to 31.03.2019
	Mr. Kulin S. Lalbhai
	Independent Director
	Mr. Humayun R. Dhanrajgir
	Independent Director up to 31.03.2019
	Mr. Savyasachi S. Sengupta
	Independent Director w.e.f 02.11.2018
	Mr. Ashish Bhargava
	Nominee Director w.e.f. 30.01.2019



Zydus Wellness

	Mr. Srivishnu Raju Nandyala	Independent Director w.e.f. 11.03.2019
	Ms. Dharmishtaben N. Raval	Independent Director w.e.f. 11.03.2019
e	Key Managerial Personnel:	
	Mr. Tarun G. Arora	Chief Executive Officer & Whole Time Director
	Mr. Umesh V. Parikh	Executive Officer [Chief Financial Officer]
	Mr. Dhaval. N. Soni	Executive Officer [Company Secretary] up to 06.02.2019
	Mr. Dhanraj P. Dagar	Executive Officer [Company Secretary] w.e.f. 06.02.2019
f	Post-Employment Benefits Plan-	
	Zydus Wellness Limited Employee Group Gratuity Scheme	
	Zydus Wellness Sikkim Employee Group Gratuity Scheme	
	Heinz India Private Limited Provident Fund [w.e.f January 30, 2019]	
	Heinz India Private Limited Employee Provident Fund [w.e.f. January 30, 2019]	
g	[*]:- M/s. Zydus Wellness - Sikkim, a partnership firm, was converted into a company, namely Zydus Nutritions Limited [ZNL], with effect from February 28, 2019, pursuant to which, it became a subsidiary of the company. Pursuant to the Scheme of Amalgamation between two subsidiaries of the company i.e. ZNL and HIPL which was sanctioned by the Hon'able National Company Law Tribunal [NCLT] vide its order dated May 10, 2019 and effective date being May 24, 2019, HIPL has been merged with ZNL w.e.f. the appointed date of March 1, 2019.	

